BX002
Crohn's Disease (AIEC+)
Key Facts
About BiomX
BiomX is a clinical-stage biotechnology company with a mission to develop precisely targeted, engineered bacteriophage therapies for chronic diseases linked to specific harmful bacteria. Its core achievement is building a proprietary discovery and synthetic biology platform to create optimized phage cocktails, advancing multiple candidates into clinical trials for acne, Crohn's disease, and colorectal cancer. The company's strategy focuses on validating its platform in high-value therapeutic areas with clear bacterial drivers, aiming to establish a new class of microbiome-sparing anti-infectives. BiomX faces the dual challenge of proving clinical efficacy in complex diseases and navigating the nascent regulatory pathway for phage-based biologics.
View full company profile